IFN‐ γ Levels and Indeterminate Rate: Comparative Analysis of Three Commercial Interferon‐Gamma Release Assays for Diagnosis of Mycobacterium tuberculosis Infection
Advances in Public Health · 2026-01 · 2026 (1)
DOI: 10.1155/adph/4671690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Public Health, online erschienen am 30.05.2026. Verfasst von Richard Kutame und 11 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The diagnosis of Mycobacterium tuberculosis infection increasingly relies on interferon‐gamma release assay (IGRA) technologies. Despite their usefulness, inconsistency in IFN‐ γ responses and the persistence of indeterminate results remain problematic across IGRA platforms. The present study aimed to comparatively assess three commercial IGRA assays (TBF‐ELISA, TBF‐FIA, and QFT‐Plus) with emphasis on IFN‐ γ production and factors influencing indeterminate results.
Methods
The study employed a cross‐sectional design and was implemented at the National Public Health and Reference Laboratory in Ghana. A total of 1148 individuals were enrolled consecutively and stratified according to their TB exposure status. Parallel testing of collected blood samples was performed with the three IGRA assays. IFN‐ γ production was quantified, and the rate of indeterminate results was analyzed. Multivariate regression analyses were performed to assess determinants of IFN‐ γ levels and indeterminate results.
Results
Significant quantitative differences in IFN‐ γ responses were observed across platforms ( p < 0.001). Active TB was the strongest predictor of IFN‐ γ release, with highest mean levels detected by TBF‐FIA (6.18 IU/mL), followed by TBF‐ELISA (3.11 IU/mL) and QFT‐Plus (2.80–2.96 IU/mL). TBF‐ELISA showed strong concordance with minimal bias versus QFT‐Plus (≤0.167 IU/mL), whereas TBF‐FIA demonstrated substantial proportional bias (>1.5 IU/mL). Indeterminate rates differed significantly (TBF‐FIA 13%, QFT‐Plus 8%, TBF‐ELISA 6%; Cochran’s Q test, p < 0.001). Demographic factors were not associated with assay failure; however, sample collection sites were significantly related. Notably, healthcare workers and TB contacts showed lower IFN‐ γ responses than expected.
Conclusion
While all three IGRAs effectively differentiate TB infection status, the variability in IFN‐ γ responses and indeterminate rates is an indication that they may not be interchangeable. TBF‐FIA demonstrated the highest variability, requiring further investigation. The findings suggest that each test has its own strengths and limitations, thus, the need for selective use depending on the clinical setting and testing purpose.
Zitieren
APA
Kutame, R., Boateng, G., Boateng, V. G., Agyemang-Bioh, F., Antwi, L., Yankey, P., Vanderpuye, V. L. N. A., Attu, J. A., Miah, B. D., Antwi, N. K., Boakyewaa, A., & Adade, R. (2026). IFN‐ γ Levels and Indeterminate Rate: Comparative Analysis of Three Commercial Interferon‐Gamma Release Assays for Diagnosis of Mycobacterium tuberculosis Infection. Advances in Public Health, 2026(1). https://doi.org/10.1155/adph/4671690
Vancouver
Kutame R, Boateng G, Boateng VG, Agyemang-Bioh F, Antwi L, Yankey P, et al. IFN‐ γ Levels and Indeterminate Rate: Comparative Analysis of Three Commercial Interferon‐Gamma Release Assays for Diagnosis of Mycobacterium tuberculosis Infection. Advances in Public Health. 2026;2026(1). doi:10.1155/adph/4671690
BibTeX
@article{Kutame2026,
author = {Kutame, Richard and Boateng, Gifty and Boateng, Vincent Gyau and Agyemang-Bioh, Florence and Antwi, Lorreta and Yankey, Patricia and Vanderpuye, Valerie Lucy Naa Aku and Attu, Joycelene Akua and Miah, Baakwa De-graft and Antwi, Nathan Kofi and Boakyewaa, Alice and Adade, Rexford},
title = {IFN‐ γ Levels and Indeterminate Rate: Comparative Analysis of Three Commercial Interferon‐Gamma Release Assays for Diagnosis of Mycobacterium tuberculosis Infection},
journal = {Advances in Public Health},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/adph/4671690}
}
EUVIMED